Clinical Experience Using Tafasitamab Plus Lenalidomide in DLBCL

,

OncLive News Network® | <b>Highlighting Key Follicular Lymphoma Data Following ASH 2024</b>

Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss their clinical practice experience using tafasitamab in relapsed/refractory DLBCL.